The healthcare community is keenly watching Synedica Retatrutide, a innovative drug targeting both GLP-1 and GIP. Initial trials suggest it appears to offer meaningful gains in reducing body weight compared to existing treatments, potentially representing a significant breakthrough in the tacklin